Date: 2015-02-09
Type of information: Loan
Company: Melinta Therapeutics (USA - CT)
Investors: Hercules Technology Growth Capital (USA - CA)
Amount: $30 million
Funding type: loan
Planned used:
- The capital raised from this financing will be used to advance Melinta’s pipeline, which includes delafloxacin, an investigational fluoroquinolone undergoing a confirmatory Phase 3 study for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI), and to repay an existing term loan and for general corporate purposes.
Others:
- • On February 9, 2015, Melinta Therapeutics announced that it has entered into a $30 million growth capital debt financing agreement with Hercules Technology Growth Capital. The initial funding of $20 million closed in December 2014. Melinta has the option, under the terms of the agreement, to draw an additional $10 million tranche in 2015 upon achievement of certain milestones.
Therapeutic area: Infectious diseases
Is general: Yes
